Shares of Kenvue rose in premarket trading Thursday after the maker of Band-Aid, Tylenol, and Listerine reported ...

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

(Reuters) -Kenvue beat quarterly profit and revenue estimates on Thursday as better-than-expected demand for cough-and-cold ...

Gordon Haskett reports that the judge overseeing the initial California Tylenol lawsuit against Kenvue (KVUE) granted summary ...

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

The Neutrogena and Aveeno owner has also increased its 2025 full-year outlook to reflect the impact of costs associated with ...

Kenvue named Kellanova Chief Financial Officer Amit Banati to that role at the over-the-counter drug maker, replacing current financial chief Paul Ruh, effective May 12. Banati has worked in executive ...

Kenvue KVUE1.58%increase; green up pointing triangle, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial ...

We expect Kenvue, with the freedom to allocate capital and invest as a stand-alone entity, to focus on its 15 priority brands (including Tylenol, Nicorette, Listerine, and Zyrtec) to drive future ...

Self care segment revenue growth updated Consumer health company Kenvue Inc. (NYSE:KVUE) on Thursday reported first-quarter ...

(Reuters) - Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold medicines like Tylenol and Benadryl helped offset a fall in ...